Enanta Pharmaceuticals Inc
General
Total Cases2
Active Cases1
Patents266
Ratings
Experience
Grade
Trend
DCT
--
--
--
PTAB
--
--
--
CAFC
--
--
--
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 02/03/25 | NOTICE OF APPEAL to the Federal Circuit as to [398] Judgment, [393] Memorandum & ORDER, by Enanta Pharmaceuticals, Inc. Filing fee: $ 605, receipt number AMADC-10820732 Fee Status: Filing Fee paid. US District Court Clerk to deliver official record to Court of Appeals by 2/24/2025. (Fiacco, Barbara) (Entered: 02/03/2025) | |
| 02/03/25 | Judge Denise J. Casper: ORDER entered. JUDGMENT (LMH) (Entered: 02/03/2025) | |
| 02/03/25 | Judge Denise J. Casper: ELECTRONIC ORDER entered granting [396] Pfizer's Motion for Extension of Time to File Motion for Attorneys Fees in connection with the Final Judgment to fifteen days after the earlier of (1) expiration of the time for appeal (if no appeal is filed) or (2) receipt by the Clerk of the mandate from the appellate court. (LMH) (Entered: 02/03/2025) | |
| 01/16/25 | Assented to MOTION for Extension of Time to File Motion for Attorney Fees by Pfizer Inc..(Proctor, Wyley) (Entered: 01/16/2025) | |
| 01/10/25 | JOINT STATEMENT of counsel Regarding Final Judgment. (Proctor, Wyley) (Additional attachment(s) added on 1/13/2025: # [1] Proposed Order). Modified to separate proposed order on 1/13/2025 (SEC). (Entered: 01/10/2025) | |
| 12/23/24 | Judge Denise J. Casper: ELECTRONIC ORDER entered. In light of the Court's Memorandum and Order entered today, D. [393] , the Court is prepared to enter judgment in favor of Defendant Pfizer Inc. ("Pfizer") on the only count in Plaintiff Enanta Pharmaceuticals, Inc.'s complaint (for infringement of the '953 patent), D. [1] ; and in favor of Pfizer on its Counterclaim II (declaration of invalidity for the '953 patent), D. [22] at 12. Pfizer's proposed order, D. [269] -1, is silent as to the only other remaining claim, its Counterclaim I (declaration of non-infringement of the '953 patent). If, in light of the rulings today, Pfizer is not pressing Counterclaim I and the parties seek to have the Court enter judgment as to Enanta's claim and Pfizer's Counterclaim II resolved in today's Memorandum and Order, the parties shall confer and file a joint statement to that effect by January 10, 2025. (Cook, Savannah) (Entered: 12/23/2024) | |
| 12/23/24 | Judge Denise J. Casper: ORDER entered. MEMORANDUM AND ORDER - the Court ALLOWS Pfizer's motion for summary judgment as to invalidity, D. [269] , and DENIES Enanta's motion for summary judgment as to infringement as moot, D. [266] . In light of these rulings, the Court DENIES the parties' respective motions to exclude expert testimony, D. [264] , [265] , [267] , [268] , as moot. (Cook, Savannah) (Entered: 12/23/2024) | |
| 11/13/24 | REDACTION to [391] Sealed document / Plaintiff Enanta Pharmaceuticals, Inc.'s Submission in Compliance with Protective Order byEnanta Pharmaceuticals, Inc.. (Attachments: # [1] Exhibit A)(Fiacco, Barbara) (Entered: 11/13/2024) | |
| 11/05/24 | SEALED Reply in Support of [377] Objection to [373] Order on Motion to Compel by Enanta Pharmaceuticals, Inc. (Cook, Savannah) (Entered: 11/05/2024) | |
| 11/04/24 | NOTICE by Pfizer Inc. Submissions of Redactions in Compliance with Paragraph 5 of Protective Order (Attachments: # [1] Attachment A, # [2] Attachment B, # [3] Attachment C, # [4] Attachment D, # [5] Attachment E)(Proctor, Wyley) (Entered: 11/04/2024) |